scholarly journals Usefulness and Safety of Early Blood Pressure Lowering After Ischemic Stroke Still Unproven

2007 ◽  
Vol 20 (3) ◽  
pp. 278-278 ◽  
Author(s):  
A SEMPLICINI
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

Effects of Blood Pressure Lowering in Patients with Acute Ischemic Stroke and Carotid Artery Stenosis

2014 ◽  
Vol 10 (3) ◽  
pp. 354-359 ◽  
Author(s):  
Mirza Jusufovic ◽  
Else Charlotte Sandset ◽  
Philip M. W. Bath ◽  
Björn W. Karlson ◽  
Eivind Berge
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Carotid Artery ◽  
Acute Ischemic Stroke ◽  
Carotid Artery Stenosis ◽  
Artery Stenosis ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

scholarly journals Age Determines the Effects of Blood Pressure Lowering During the Acute Phase of Ischemic Stroke

Hypertension ◽  
2009 ◽  
Vol 54 (4) ◽  
pp. 769-774 ◽  
Author(s):  
Rogelio Leira ◽  
Mónica Millán ◽  
Exuperio Díez-Tejedor ◽  
Miguel Blanco ◽  
Joaquín Serena ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Acute Phase ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

scholarly journals Comparative effects of intensive-blood pressure versus standard-blood pressure-lowering treatment in patients with severe ischemic stroke in the ENCHANTED trial

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jatinder S. Minhas ◽  
Xia Wang ◽  
Richard I. Lindley ◽  
Candice Delcourt ◽  
Lili Song ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Blood Pressure Lowering ◽  
Pressure Lowering ◽  
Intensive Blood Pressure

scholarly journals Effects of Blood Pressure–Lowering Treatment in Different Subtypes of Acute Ischemic Stroke

Stroke ◽  
2015 ◽  
Vol 46 (3) ◽  
pp. 877-879 ◽  
Author(s):  
Else Charlotte Sandset ◽  
Mirza Jusufovic ◽  
Per Morten Sandset ◽  
Philip M.W. Bath ◽  
Eivind Berge
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

scholarly journals Antihypertensives and Statin Therapy for Primary Stroke Prevention

Stroke ◽  
2021 ◽  
Author(s):  
Jackie Bosch ◽  
Eva M. Lonn ◽  
Gilles R. Dagenais ◽  
Peggy Gao ◽  
Patricio Lopez-Jaramillo ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Ischemic Stroke ◽  
Cardiovascular Risk ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Pressure Lowering ◽  
Stroke Subtype ◽  
Unique Identifier ◽  
Pressure Lowering

Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation–3) found that antihypertensive therapy combined with a statin reduced first stroke among people at intermediate cardiovascular risk. We report secondary analyses of stroke outcomes by stroke subtype, predictors, treatment effects in key subgroups. Methods: Using a 2-by-2 factorial design, 12 705 participants from 21 countries with vascular risk factors but without overt cardiovascular disease were randomized to candesartan 16 mg plus hydrochlorothiazide 12.5 mg daily or placebo and to rosuvastatin 10 mg daily or placebo. The effect of the interventions on stroke subtypes was assessed. Results: Participants were 66 years old and 46% were women. Baseline blood pressure (138/82 mm Hg) was reduced by 6.0/3.0 mm Hg and LDL-C (low-density lipoprotein cholesterol; 3.3 mmol/L) was reduced by 0.90 mmol/L on active treatment. During 5.6 years of follow-up, 169 strokes occurred (117 ischemic, 29 hemorrhagic, 23 undetermined). Blood pressure lowering did not significantly reduce stroke (hazard ratio [HR], 0.80 [95% CI, 0.59–1.08]), ischemic stroke (HR, 0.80 [95% CI, 0.55–1.15]), hemorrhagic stroke (HR, 0.71 [95% CI, 0.34–1.48]), or strokes of undetermined origin (HR, 0.92 [95% CI, 0.41–2.08]). Rosuvastatin significantly reduced strokes (HR, 0.70 [95% CI, 0.52–0.95]), with reductions mainly in ischemic stroke (HR, 0.53 [95% CI, 0.37–0.78]) but did not significantly affect hemorrhagic (HR, 1.22 [95% CI, 0.59–2.54]) or strokes of undetermined origin (HR, 1.29 [95% CI, 0.57–2.95]). The combination of both interventions compared with double placebo substantially and significantly reduced strokes (HR, 0.56 [95% CI, 0.36–0.87]) and ischemic strokes (HR, 0.41 [95% CI, 0.23–0.72]). Conclusions: Among people at intermediate cardiovascular risk but without overt cardiovascular disease, rosuvastatin 10 mg daily significantly reduced first stroke. Blood pressure lowering combined with rosuvastatin reduced ischemic stroke by 59%. Both therapies are safe and generally well tolerated. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00468923.

Sign in / Sign up

Export Citation Format

Share Document